source
- Hims reports $33 million loss after shifting focus to GLP-1 marketHims said its latest earnings were hit by a $33 million charge tied to a strategic shift toward GLP-1 treatments. The charge stems from costs of redirecting product development and marketing resou…
- FDA reopens comment period for BHT and launches post-market chemical safety programThe U.S. Food and Drug Administration announced two actions as part of its ongoing food chemical safety agenda. The agency will reopen the comment period for the Request for Information on butylat…